Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis
Trial details
- Registry ID
- NCT07362017
- Phase
- Phase 3
The FDA approved Ponesimod on 18 Mar 2021.
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque PsoriasisNCT07362017 | Vanda Pharmaceuticals | Phase 3 | Recruiting | 2028-08Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2021-03-18Day | Ponesimod | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA213498", "applicant_as_listed_by_fda": "VANDA PHARMS INC", "brand_names": ["PONVORY"], "active_ingredients": ["PONESIMOD"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20210318", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |